ITeos Therapeutics Reports Q1 2025 Financial Results
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $16
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $21
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $16
ITeos Therapeutics Analyst Ratings
ITeos Therapeutics | 10-Q: Q1 2025 Earnings Report
ITeos Therapeutics 1Q Loss $34.6M >ITOS
Express News | ITeos Therapeutics Q1 EPS $(0.80) Beats $(0.95) Estimate
ITeos Therapeutics: Cash, Investment Balance of $624.3 M as of March 31 Expected to Provide Runway Through 2027 >ITOS
Express News | Iteos Reports First Quarter 2025 Financial Results and Provides Business Updates
ITeos Reports First Quarter 2025 Financial Results and Provides Business Updates
Positive Week for ITeos Therapeutics, Inc. (NASDAQ:ITOS) Institutional Investors Who Lost 38% Over the Past Year
Companies Like ITeos Therapeutics (NASDAQ:ITOS) Are In A Position To Invest In Growth
$ITOS Stock Is up 7% Today. Here's What We See in Our Data.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
BeiGene Slips on Decision to Halt Lung Cancer Program
Piper Sandler Initiates ITeos Therapeutics(ITOS.US) With Buy Rating, Announces Target Price $16
ITeos Therapeutics (ITOS) Gets a Buy From Piper Sandler
ITeos To Present Preclinical Data On Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, And Novel PTPN1/2 Inhibitor At The AACR Annual Meeting 2025